



**ABN: 12 107 903 159**

## **ASX ANNOUNCEMENT**

### **Helicon Director Resignation & Appointment**

#### **Announcement Summary:**

Mr Graeme Boden appointed Non Executive Director  
Dr Arthur Emmett resigns as Non Executive Director

---

**PERTH, May 28<sup>th</sup> 2009.** HELICON GROUP LIMITED (ASX: HCG) announces the resignation of Dr Arthur Emmett as Non Executive Director of Helicon Group Limited.

Dr Emmett joined the Helicon Board in June 2006 and was a significant contributor in the development of the Company's China strategy. He has resigned for personal reasons unrelated to his Helicon directorship.

The Board welcomes the appointment of Mr Graeme Boden as Non Executive Director. Mr Boden brings a wealth of experience as Company Director and Secretary of ASX listed companies. He has held those offices with biotechnology and pharmaceutical companies for over 20 years, in addition to over 30 years experience in the resource sector. He is presently the principal of Boden Corporate Services Pty Ltd and also a director of S & A Capital Pty Ltd. Mr Boden will retain his role as Helicon's Company Secretary.

"On behalf of Helicon and the Board I welcome Graeme's appointment to the Board and also would like to sincerely thank Arthur Emmett for his contribution to Helicon and express our regret at his departure. His pharmaceutical business experience together with his experience in running businesses in China has been invaluable to the company" said Peter Abrahamson, Helicon's CEO.

#### **About the Helicon Group**

Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets of North Asia, specifically China and to participate in the

significant growth that has been projected for these markets over the next 25 years.

Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for.

Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on western markets. Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing, and sales.

**For further information please contact:**

Peter Abrahamson  
Helicon Group Limited  
Suite 3, 257 York Street,  
Subiaco WA 6006  
Tel: +61 411 336 330  
Email: [peter@helicongroup.com.au](mailto:peter@helicongroup.com.au)  
Website: [www.helicongroup.com.au](http://www.helicongroup.com.au)